TP53 and breast carcinoma: In that respect, Angus et al. (2019) have recently reported on the genomic landscape of MBC and showed more frequent mutations in ESR1, TP53, NF1, AKT1, KMT2C and PTEN in ER+/HER2‐ metastatic lesions than in primary breast carcinomas.